Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib and Nivolumab for Advanced BRAF Wildtype Melanoma
NCT04375527Phase 2Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of binimetinib in melanoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Dec 2020; status: terminated.
02
Drugs
binimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04375527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375527.